A vaccine based on conserved regions of M1 and NP within a modified vaccinia Ankara (MVA) vector showed encouraging immunogenicity data
Contact your GP if you notice no improvement after 46 weeks of treatment, experience worsening neurological symptoms, or develop new unexpected symptoms
Safety: Handle using appropriate personal protective equipment (PPE) such as gloves, lab coat, and eye protection, within a controlled laboratory environment
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
If clear, slowly push the plunger to inject the vitamin B12
